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processing and cell surface expression. Since development and
progression of tumors is not only dependent on cancer cells
themselves but also on the active contribution of the stromal
cells, e.g. by secreting growth supporting factors, enzymes
degrading the extracellular matrix or angiogenic factors, the
tumor stroma may also serve as a target for immune interven-
tion. To this end several antigens have been identified which
are induced or upregulated on the tumor stroma. Tumor
stroma-associated antigens are characterized by an otherwise
restricted expression pattern, particularly with respect to differ-
entiated tissues, and they have been successfully targeted by
passive and active immunotherapy in preclinical models. More-
over, some of these strategies have already been translated into
clinical trials.
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Metastasis is the major cause of deaths in patients with solid
tumors. Occult micrometastatic spread of tumor cells might be
the seed for the occurrence of overt metastases in distant
organs within the years following successful surgical resection
of the primary tumor. The two major approaches to detect such
‘‘minimal residual disease’’ are immunocytochemical staining
and polymerase chain reaction analysis. These assays are sensi-
tive enough to detect a single disseminated tumor cell (DTC) in
the background of millions of normal cells [Pantel and Braken-
hoff. Nat Rev Cancer 2004;4:1–9]. For epithelial tumors, cytokera-
tins have become the best marker for the immunocytochemical
detection of DTCs in blood, lymph nodes and bone marrow
(BM).
Micrometastatic cells in BM can be easily collected from the
iliac crest, and BM seems to be a common homing organ for DTCs
derived from various types of malignant epithelial tumors (e.g.,
breast, lung, prostate or colorectal cancer). DTCs are present in
BM samples of 20–40% of patients even in the absence of lymph
node metastases (stage N0) or clinical signs of overt distant
metastases (stage M0). A pooled analysis on 4703 breast cancer
patients [Braun et al., NEJM 2005;353:793–802] has shown that
the detection of DTC in BM is a marker for an increased risk to
develop metastatic relapse. The molecular and biochemical char-
acterization of DTCs helps to identify progression markers
towards overt metastases and new therapeutic targets for thera-
pies that are specifically directed against minimal residual dis-
ease. This information may refine the current DTC detection
approaches, which the major goal of the EU-funded consortium
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A stringent control of mitosis is mandatory to warrant the
accurate segregation of sister chromatids in dividing cells.
Eukaryotic cells have evolved sophisticated mechanisms to
monitor faithful progression through each phase of mitosis in
order to prevent the occurrence of aneuploid daughter cells.
Polo like kinase 1 (Plk1) has been identified to be a key player
for G2-M transition and mitotic progression in both, normal
and tumor cells. Multiple essential roles have been assigned
to Plk1 at the entry into M-phase, mitotic spindle formation,
condensation and separation of chromosomes, exit from mito-
sis by activation of the anaphase-promoting complex and in
cytokinesis.
We have employed chimeric antisense oligonucleotides and
siRNA to investigate the molecular alterations after targeted
interference with Plk1 in a multitude of human cancer cells.
Suppression of Plk1 mRNA inevitably resulted in a dramatic
increase of the mitotic index followed by the onset of apoptosis.
Mitotically arrested cells displayed randomly separated con-
densed chromosomes and the occurrence of multiple spindle
poles with well-formed asters. Induction of apoptosis was
strictly dependent on cell cycle progression: Genetically engi-
neered RKO human colon adenocarcinoma cells with inducible
expression of the cdk inhibitor p27Kip1 were completely refrac-
tory to Plk1 depletion-induced apoptosis when they were
arrested in the G1 phase of the cell cycle. Various mitotic mark-
ers including MPM-2, cdc25c, cyclinB1, or phospho-histone H3
were investigated to explore the molecular consequences of
Plk1 depletion. While most marker proteins only showed altera-
tions typical for mitosis, modifications of cdc25c allowed distinc-
tion between mitotic targeting via Plk1 or via other mechanisms,
such as microtubule inhibitors. cdc25c was fully phosphorylated
solely in paclitaxel-treated cells, while it was only partially
phosphorylated in Plk1 depleted cells despite the fact that both
treatments caused a profound mitotic arrest. This differential
phosphorylation of cdc25c was used to test whether a pharma-
cological inhibitor of Plk1 kinase activity would exert the same
cellular effects as interference with Plk1 on an mRNA level. In
deed, pharmacological intervention with Plk1 using a specific
Plk1 kinase inhibitor induced exactly the same molecular altera-
tions and displayed the cell cycle-dependent cytotoxicity as Plk1
interference on an mRNA level. Taken together, these data sub-
stantiate the attractiveness of Plk1 as candidate for mitotic tar-
geting of cancers.
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